Generative AI for Sleep Promotion
20 de julho de 2026 atualizado por: New York University
Sleep is a major public health concern in the United States.
Major guidelines recommend that adults obtain at least 7 hours of sleep per night.
More than 25% of U.S. adults do not meet this recommendation, and 14.5% report difficulty falling asleep on most days or every day during the past month.
The investigators developed a low-cost, easily accessible sleep intervention using artificial intelligence (AI) technologies.
The purpose of this study is to examine the effect of this intervention on sleep outcomes among U.S. adults.
Visão geral do estudo
Status
Recrutamento
Condições
Intervenção / Tratamento
Descrição detalhada
After providing informed consent, participants will complete a baseline assessment and then be randomized to either the AI chatbot intervention or a waitlist control.
The intervention group will receive immediate access to the AI-powered sleep chatbot for 2 weeks, while the waitlist control group will continue their usual sleep habits without chatbot access.
Following the post-intervention assessment, participants in the waitlist control group will receive access to the chatbot.
Follow-up assessments will be conducted at 3 and 6 months after randomization.
Tipo de estudo
Intervencional
Inscrição (Estimado)
60
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
- Nome: Liu
- Número de telefone: 212-992-5994
- E-mail: xl5272@nyu.edu
Locais de estudo
-
-
New York
-
New York, New York, Estados Unidos, 10010
- Recrutamento
- New York University
-
New York, New York, Estados Unidos, 10010
- Concluído
- New York University
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Não
Descrição
Inclusion Criteria:
- Aged 18-75 years
- had a raw score of 23 or higher on the Patient-Reported Outcomes Measurement Information System (PROMIS™) Sleep Disturbance
- had a smartphone and be able to access the internet
- willing and able to participate through text messages on a smartphone
- able to read and understand English
Exclusion Criteria:
- pregnant or lactating
- concurrently participating in other research studies focused on lifestyle modifications
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Intervention
Participants will receive access to an AI-based chatbot and engage with it via text messaging for 2 weeks.
|
Participants engage with an AI chatbot for two weeks to learn personalized education and skills regarding sleep promotion
|
|
Comparador Ativo: Waitlist control
Participants will continue their usual sleep habits for 2 weeks without access to the AI-based chatbot.
After the 2-week waitlist period, participants will receive access to the chatbot and engage with it via text messaging for 2 weeks.
|
Participants engage with an AI chatbot for two weeks to learn personalized education and skills regarding sleep promotion
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Fitbit-measured sleep duration
Prazo: Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
Sleep duration will be measured objectively using Fitbit and defined as the total amount of time spent asleep during the primary sleep period, expressed in minutes.
|
Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Fitbit-measured sleep onset
Prazo: Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
Sleep onset will be measured objectively using Fitbit and defined as the time from attempting to fall asleep to sleep onset, expressed in minutes.
|
Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
|
Fitbit-measured sleep efficiency
Prazo: Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
Sleep efficiency will be measured objectively using Fitbit and defined as the percentage of time spent asleep while in bed, expressed as a percentage (%).
|
Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
|
Fitbit-measured wake after sleep onset
Prazo: Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
Wake after sleep onset will be measured objectively using Fitbit and defined as the total amount of time participants are awake after initially falling asleep until the final awakening, expressed in minutes.
|
Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
|
Perceived sleep quality
Prazo: Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
Perceived sleep quality measured by the Pittsburgh Sleep Quality Index.
The total score ranges from 0 to 21, with higher scores indicating worse sleep quality.
|
Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
|
Daytime sleepiness
Prazo: Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
Daytime sleepiness will be measured using the Epworth Sleepiness Scale.
The total score ranges from 0 to 24, with higher scores indicating greater daytime sleepiness.
|
Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
|
Sleep hygiene
Prazo: Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
Sleep hygiene will be measured using the Sleep Hygiene Index.
The total score ranges from 13 to 65, with a higher score indicating poorer sleep hygiene (a worse outcome).
|
Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
|
Sleep environment
Prazo: Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
Sleep Environment measured by the Assessment of Sleep Environment
|
Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
|
Number of awakenings
Prazo: Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
Number of awakenings will be measured objectively using Fitbit and defined as the total number of wake episodes occurring during the primary sleep period, expressed as the number of awakenings.
|
Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
|
Light sleep duration
Prazo: Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
Light sleep duration will be measured objectively using Fitbit and defined as the total time spent in the light sleep stage during the primary sleep period, expressed in minutes.
|
Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
|
Deep sleep duration
Prazo: Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
Deep sleep duration will be measured objectively using Fitbit and defined as the total time spent in the deep sleep stage during the primary sleep period, expressed in minutes.
|
Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
|
Rapid eye movement sleep duration
Prazo: Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
Rapid eye movement sleep duration will be measured objectively using Fitbit and defined as the total time spent in the rapid eye movement sleep stage during the primary sleep period, expressed in minutes.
|
Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
|
Wake duration
Prazo: Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
Wake duration will be measured objectively using Fitbit and defined as the total time spent awake during the primary sleep period, expressed in minutes.
|
Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
|
Dysfunctional beliefs and attitudes about sleep
Prazo: Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
Dysfunctional beliefs and attitudes about sleep will be measured using the Dysfunctional Beliefs and Attitudes about Sleep Scale (DBAS-16).
The total scores range from 0 to 10, with a higher score indicating more dysfunctional beliefs and attitudes about sleep.
|
Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
|
Perceived stress
Prazo: Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
Perceived stress will be measured using the Perceived Stress Scale-4.
The total score ranges from 0 to 16, with a higher score indicating greater perceived stress.
|
Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
|
Anxiety
Prazo: Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
Anxiety will be measured using the Generalized Anxiety Disorder-2.
The total score ranges from 0 to 6, with a higher score indicating greater anxiety symptom severity.
|
Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
|
Fatigue
Prazo: Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
Fatigue will be measured using the Fatigue Severity Scale.
The total score ranges from 1 to 7, with a higher score indicating greater fatigue severity.
|
Baseline, 2-week post-intervention, and 3- and 6-month follow-ups
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
1 de outubro de 2025
Conclusão Primária (Estimado)
1 de julho de 2027
Conclusão do estudo (Estimado)
31 de dezembro de 2027
Datas de inscrição no estudo
Enviado pela primeira vez
21 de janeiro de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
20 de julho de 2026
Primeira postagem (Real)
22 de julho de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
22 de julho de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
20 de julho de 2026
Última verificação
1 de julho de 2026
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- FY2024-9037
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
NÃO
Descrição do plano IPD
To protect participants' personal information and privacy
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .